Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARLANEC
2024-515948-23-00Phase 3Authorised
- Sponsor
- IFCT
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in neuroendocrine carcinoma (NEC) and gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) comparing Tarlatamab with Standard-of-care chemotherapy (2 arms). Primary endpoint: Overall survival (OS) in patients who received at least one dose of treatment. Planned start Sep 2025; status: authorised.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine carcinoma (NEC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2024-515948-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515948-23-00.